Brainstorm cell therapeutics receives refusal to file letter from fda for its new biologics license application for nurown for the treatment of als

New york , nov. 10, 2022 /prnewswire/ -- brainstorm cell therapeutics inc. (nasdaq: bcli), a leading developer of cellular therapies for neurodegenerative diseases, today announced that the company has received a refusal to file letter from the u.s. food and drug administration (fda) regarding the company's new biologics license application (bla) for nurown for the treatment of als. the fda has indicated that the company can request a type a meeting to discuss the content of the refusal to file letter.
BCLI Ratings Summary
BCLI Quant Ranking